Wai Chun Bio-Technology flags sharply narrower interim loss

Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has shared an update.

Wai Chun Bio-Technology Limited has issued a profit alert indicating that its net loss for the six months ended 31 December 2025 is expected to narrow to no more than HK$6.0 million, compared with a loss of about HK$13.1 million a year earlier. The improvement is mainly attributed to higher revenue and lower finance costs during the period, although the figures are based on unaudited management accounts and the company has cautioned shareholders and potential investors to exercise care when dealing in its shares until the final interim results are released.

The company is still finalising its interim results for the period, which have yet to be reviewed by the audit committee, and it plans to publish the full set of figures within the timeframe required by Hong Kong listing rules. The anticipated substantial reduction in losses suggests progress in Wai Chun Bio-Technology’s financial performance, potentially easing pressure on the balance sheet and providing a modest positive signal to investors despite the group remaining in a loss-making position.

More about Wai Chun Bio-Technology Ltd.

Wai Chun Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands and engaged through its subsidiaries in bio-technology related businesses. The group is listed on the Main Board of the Stock Exchange of Hong Kong under stock code 660 and is overseen by a board led by chairman and chief executive officer Lam Ka Chun.

Average Trading Volume: 147,145

Technical Sentiment Signal: Buy

Current Market Cap: HK$49.97M

For an in-depth examination of 0660 stock, go to TipRanks’ Overview page.